Adherium Ltd. · ASX:ADR
Adherium — Investor Webinar June 2026
19 slides from Adherium's conference presentation, June 2026
Slide 1: Adherium Path to U.S. Value-Based Contracts
Smarter Monitoring. Better Breathing. Lower Costs. Adherium Path to U.S. Value-Based Contracts INVESTOR WEBINAR · ASX: ADR June 2026
Slide 2: Disclaimer and Forward-Looking Statement
Disclaimer and Forward-Looking Statement The material contained herein is of a general nature & has only been prepared as c. the potential for delays in regulatory approvals a presentation aid. This presentation does NOT contain all of the information that may be required for evaluating Adherium Lim
Slide 3: Proprietary Hailie SmartInhalers placed on the patient's inhaler. Every dose becomes data.
2 01 WHAT WE DO Proprietary Hailie® SmartInhalers® placed on the patient's inhaler. Every dose becomes data. The patient uses their inhaler normally. We turn every dose into objective, longitudinal data that care teams and payers can act on. Hailie SmartInhaler 1 12 FDA-cleared sensors clip to the p
Slide 4: The most expensive events in respiratory care are the most preventable.
02 THE PROBLEM The most expensive events in respiratory care are the most preventable. ~40M $59.6B ~$18k Americans live with chronic Annual U.S. cost of COPD alone — Average cost per severe COPD respiratory disease such as asthma about half tied to hospitalisations patient, much of it avoidable with
Slide 5: RPM revenue today. Value-based care tomorrow.
03 THE MAP WE ARE FOLLOWING RPM revenue today. Value-based care tomorrow. One platform, two stages. We are executing Stage 1 now and building the assets that unlock Stage 2. Activated Outcomes Covered Initiate RPM and lives under VBC Patients economics contracts contracts STRONG FOUNDATION BUILDING
Slide 6: Adherium's recurring revenue is growing.
04 STAGE 1 · PROOF IT IS WORKING Adherium’s recurring revenue is growing. A$344k 3 quarters 2,600+ RPM subscription revenue, Of consecutive record Activated patients on the 3QFY26 — up 101% on the recurring RPM revenue platform (+84% QoQ) prior quarter Activations and shipments are growing QoQ. The
Slide 7: Two tailwinds, converging.
05 WHY NOW Two tailwinds, converging. Remote Patient Monitoring (RPM) Value-Based Care (VBC) REIMBURSEMENT PAYS US TODAY. THE RULES VALUE-BASED CARE PAYS US NEXT. THE CHANGED JAN 1 SO WE GET PAID TO MONITOR FAR HEALTHCARE ORGANIZATIONS WHO HOLD THE COST MORE PATIENTS. NOW HAVE A REASON TO PAY US A S
Slide 8: iCARE: Landmark real-world evidence generating metrics payers actually pay for.
iCARE Quality 06 THE EVIDENCE Improvement Study iCARE: Landmark real-world evidence generating metrics payers actually pay for. Real-world results from the Intermountain Health (IMH) iCARE program — over 1,000 asthma and COPD patients, presented at American Thoracic Society (ATS) 2026. These outcome
Slide 9: Engagement software is abundant. Our respiratory data is rare.
07 THE MOAT Engagement software is abundant. Our respiratory data is rare. WHAT WE BUILD · THE MOAT WHAT WE PARTNER · INTERCHANGEABLE Proprietary devices Engagement apps The only smart sensors covering both MDIs and DPIs; AND Interchangeable across vendors. We run Hailie® Care live adherence and tec
Slide 10: Value-Based Care
Value-Based Care Why these contracts exist, who pays for them, and who we sell to. Guidance for navigating the complex U.S. system. John Perry Chief Commercial Officer
Slide 11: We get paid a share of what we save.
08 VALUE-BASED CARE, IN PLAIN ENGLISH We get paid a share of what we save. Money and risk flow down this chain. Whoever carries the cost of a respiratory population is our buyer. Funders Health plans Risk-bearing Patients providers Government (Medicare, → Insurers and Medicare →Accountable Care Orga
Slide 12: The model is proven — just not yet in respiratory.
09 THESE DEALS ARE REAL The model is proven — just not yet in respiratory. Leading digital-health companies already get paid on outcomes and shared savings. Only Adherium has proprietary respiratory data. Teladoc / Livongo (NYSE: TDOC $1.3BN USD cap) Omada Health (NASDAQ: OMDA $1BN USD cap) Outcomes
Slide 13: Prevent the admission. Share the savings.
10 HOW THE ECONOMICS WORK Prevent the admission. Share the savings. 1 2 3 4 The cost event The intervention The savings pool Adherium's share A single severe asthma / COPD →Our inhaler data drives earlier →Avoided admissions become a →We take a deliberately modest admission can run $20,000– action;
Slide 14: Near-term proof points.
11 THE NEXT SIX MONTHS Near-term proof points. 1 2 3 Scale RPM Grow the evidence Land the first VBC deal Continue driving growing recurring Grow our proprietary RPM dataset Target a lighthouse VBC partnership fee-for service revenue across more patients and replicate in the near term and stand up th
Slide 15: The Thesis
THE THESIS Adherium’s leading proprietary respiratory data layer — reimbursed today, proven in outcomes and designed for value-based care. Growing recurring RPM revenue Real-world evidence payers already pay for A proprietary data moat competitors cannot easily replicate A clear, near-term path to t
Slide 16: Thank You
Thank You For more information, contact: Dawn Bitz, CEO DawnB@adherium.com
Slide 17: Key Terms, and Acronyms
Key Terms, and Acronyms Commercial / US Healthcare Industry Terms ACO Accountable Care Organization LTV Lifetime Value ADR Adherium Limited (ASX: ADR) MA Medicare Advantage AI Artificial Intelligence MDI Metered Dose Inhaler AIRQ Asthma Impairment and Risk Questionnaire MMA Medication Management for
Slide 18: The entities that hold respiratory risk.
05 VALUE BASED CARE 101 The entities that hold respiratory risk. Medicare Advantage (MA) Accountable Care Risk-bearing health plans Organisation (ACO) & systems Shared Savings Asthma and COPD admissions costs / Share savings on total cost of care; Under downside contracts, Healthcare Effectiveness D
Slide 19: Where our commercial strategy starts.
A2 IDEAL CUSTOMER & MARKET Where our commercial strategy starts. TAM SAM ICP Every U.S. risk-bearing organisation with Those holding asthma / COPD risk Ready to act on between-visit data, a respiratory population. where RTM and RPM are reimbursed. with real downside exposure today. Our ideal first c